In Vivo Electrophysiological Assay Service
Inquiry
In vivo electrophysiological assay are a critical component of preclinical research, serving to evaluate the functional impact of candidate anticancer drugs or therapeutics on cardiovascular, neurological, structural, and microcirculatory systems. Alfa Cytology provides comprehensive in vivo Electrophysiological assay services, encompassing electrocardiography (ECG) telemetry, X-ray imaging, laser speckle contrast imaging, and EEG/EMG monitoring, to support your oncology drug development programs.
Introduction to In Vivo Electrophysiological Assay
Electrophysiological assay serve as a critical bridge connecting molecular and pathological findings with whole-animal functional outcomes, providing real-time, integrative information in oncology drug development that cannot be obtained from molecular lysates or tissue sections alone. Through systematic electrophysiological assessments, researchers can quantitatively evaluate drug effects on cardiac electrophysiology, bone structure, microcirculatory dynamics, and neurological function, generating key functional evidence for drug-induced QTc prolongation, bone metastasis progression, tumor vascular response, and neurotoxicity risks. These data directly support cardiovascular safety evaluation, structural imaging assessment, hemodynamic monitoring, and neurotoxicity profiling, providing indispensable physiological evidence for dose selection and risk mitigation, ultimately facilitating the translation of oncology therapeutics from preclinical research to clinical development.
Fig. 1 Predictive value of the ECG score for cardiotoxicity determined using the ROC analysis. (Pohl J, et al.; 2021)
Our Services
Alfa Cytology offers a comprehensive suite of in vivo electrophysiological assay designed to assess the functional impact of cancer therapies across multiple organ systems in real time, ranging from cardiovascular and neurological function to structural integrity and microcirculatory dynamics.
Our electrophysiological platform integrates ECG telemetry, X-ray imaging, laser speckle contrast imaging, and EEG/EMG monitoring to deliver multidimensional safety and efficacy data. Whether you are evaluating cardiac safety liabilities, monitoring bone metastasis progression, assessing tumor vascular response, or investigating neurotoxicity risks, our services provide the critical physiological evidence needed to support confident go/no-go decisions and regulatory submissions.
Test Types
Electrocardiography (ECG) Assay
- Quantitatively analyzes key parameters including heart rate, PR interval, QRS duration, QT interval, and rate-corrected QTc interval, with identification of potential proarrhythmic signals such as QTc prolongation.
- Supports both acute acquisition under anesthesia and long-term telemetric monitoring in freely moving conscious animals for cardiovascular safety pharmacology assessment.
- Enables non-invasive visualization of the skeletal system, thoracic, and abdominal organs, supporting bone metastasis monitoring, assessment of tumor-induced bone erosion, and pulmonary metastatic lesion screening.
- Delivers high-resolution digital images with quantitative bone mineral density analysis and region-of-interest measurement for pharmacodynamic evaluation in bone metastasis models and tumor burden assessment.
Laser Speckle Contrast Imaging (LSCI)
- Provides real-time, full-field perfusion imaging without the need for fluorescent labels or contrast agents, enabling quantitative analysis of blood perfusion volume and vascular morphology.
- Supports tumor angiogenesis assessment, pharmacodynamic monitoring of anti-angiogenic agents, and hemodynamic studies across multiple organs.
Electroencephalography / Electromyography (EEG/EMG)
- EEG supports long-term recording in conscious freely moving animals via intracranial or cortical electrode implantation, enabling detection of epileptiform discharges and spectral analysis of brain rhythms.
- EMG supports nerve conduction velocity measurement and motor unit potential analysis for neurotoxicity assessment and safety evaluation of ADC therapeutics.
Supported Therapeutic Modalities
Our in vivo electrophysiological assay services broadly support diverse cancer therapy R&D, providing critical functional data for cardiovascular safety evaluation, structural imaging assessment, hemodynamic monitoring, and neurotoxicity profiling across a wide range of therapeutic approaches.
Available Model Systems
Our in vivo electrophysiological assay services are applicable to a wide range of cancer research and safety evaluation models, providing reliable electrophysiological data across different stages of drug development.
- Tumor Models: CDX/PDX tumor-bearing models (subcutaneous and orthotopic), bone metastasis models, brain metastasis models, angiogenesis models.
- Safety Evaluation Models: Cardiovascular safety pharmacology models (telemetry-equipped rats, dogs, and non-human primates), neurotoxicity assessment models (EEG/EMG monitoring), vascular function models (laser speckle contrast imaging)
Applications of Our Electrophysiological Assay Service
Cardiovascular Safety Evaluation
Evaluation of drug-induced QTc prolongation and arrhythmogenic risk via electrocardiography (ECG) telemetry to support cardiac safety assessment and IND-enabling studies.
Assessment of anti-angiogenic drug efficacy through laser speckle contrast imaging to determine optimal therapeutic windows, combined with X-ray imaging for morphological evaluation of anti-tumor activity in bone metastasis models.
Combination Strategy Optimization
Simultaneous multi-system Electrophysiological monitoring to evaluate the comprehensive effects of combination regimens on cardiovascular, neurological, and microvascular systems, supporting safety window determination and combination strategy advancement.
Neurotoxicity Risk Assessment
Evaluation of drug-induced central nervous system toxicity and peripheral neuropathy via EEG and EMG monitoring, particularly applicable to ADCs, oncolytic viruses, and CNS-penetrant small molecule agents.
Alfa Cytology offers flexible in vivo electrophysiological assay service solutions tailored to your project requirements—whether a specific assay for a single endpoint or an integrated testing portfolio supporting the entire preclinical drug development cycle. If you are interested in learning how our in vivo electrophysiological assay services can accelerate your oncology drug development programs, please don't hesitate to contact us.
Reference
- Pohl J, et al. ECG Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity. Cancers (Basel). 2021;13(6):1197.
For research use only.
Related Services
